- Home
- REBN vs QNCX Comparison
REBN vs QNCX Comparison
Compare REBN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | QNCX |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 19.9M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | REBN | QNCX |
|---|---|---|
| Price | $2.16 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.5K | ★ 1.4M |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $1.36 | $0.08 |
| 52 Week High | $3.45 | $4.55 |
Technical Indicators
Market Signals| Indicator | REBN | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 60.55 |
| Support Level | $2.07 | $1.17 |
| Resistance Level | $2.21 | $1.50 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 0.00 | 15.28 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.